Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | CCR6 | P51684 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4684388 | 1.00 | KDM4E (0.42) | KDM4EL3MBTL1GAANPC1RAB9A | |
| SCHEMBL4684391 | 1.00 | KDM4E (0.42) | KDM4EL3MBTL1GAANPC1RAB9A | |
| SCHEMBL4684389 | 1.00 | KDM4E (0.42) | KDM4EL3MBTL1GAANPC1RAB9A | |
| SCHEMBL4684386 | 1.00 | KDM4E (0.42) | KDM4EL3MBTL1GAANPC1RAB9A | |
| SCHEMBL11997066 | 0.83 | LMNA (0.37) | KDM4EL3MBTL1GAANPC1RAB9A | |
| SCHEMBL11973478 | 0.80 | PDE10A (0.41) | KDM4EL3MBTL1NPC1RAB9ALMNA | |
| SCHEMBL32666305 | 0.79 | AMY1A (0.47) | KDM4EL3MBTL1GAAALDH1A1KMT2A | |
| SCHEMBL31569394 | 0.79 | TRIM24 (0.45) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL29073705 | 0.79 | TRIM24 (0.45) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL30391123 | 0.79 | TRIM24 (0.45) | ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111518166-B | Peptidomimetics compound or pharmaceutically acceptable salt thereof, and preparation method and application thereof | 中国药科大学 | 2023-01-31 | — | — | CN | disclosed |
| US-7423154-B2 | Asymmetric process for the preparation of diarylethylpiperazines derivatives and novel asymmetric diarylmethylamines as intermediates | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| EP-1368325-B1 | NEW ASYMMETRIC PROCESS FOR THE PREPARATION OF DIARYLMETHYLPIPERAZINES DERIVATIVES AND NOVEL ASYMMETRIC DIARYLMETYLAMINES AS INTERMEDIATES | ASTRAZENECA AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| US-7045625-B2 | Asymmetric process for the preparation of diarylethylpiperazines derivatives and novel asymmetric diarylmethylamines as intermediates | ASTRAZENECA AB (SE) | 2006-05-16 | — | — | US | disclosed |
| US-20060074238-A1 | Asymmetric process for the preparation of diarylethylpiperazines derivatives and novel asymmetric diarylmethylamines as intermediates | ASTRAZENECA AB (SE) | 2006-04-06 | — | — | US | disclosed |
| US-20040077861-A1 | Asymmetric process for the preparation of diarylethylpiperazines derivatives and novel asymmetric diarylmethylamines as intermediates | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | US | disclosed |
| EP-1368325-A1 | NEW ASYMMETRIC PROCESS FOR THE PREPARATION OF DIARYLMETHYLPIPERAZINES DERIVATIVES AND NOVEL ASYMMETRIC DIARYLMETYLAMINES AS INTERMEDIATES | AstraZeneca AB (SE) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002070492-A1 | NEW ASYMMETRIC PROCESS FOR THE PREPARATION OF DIARYLMETHYLPIPERAZINES DERIVATIVES AND NOVEL ASYMMETRIC DIARYLMETYLAMINES AS INTERMEDIATES | ASTRAZENECA AB (SE) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074238-A1 | Asymmetric process for the preparation of diarylethylpiperazines derivatives and novel asymmetric diarylmethylamines as intermediates | SRM, SULT2A1, PNMT | KDM4E 936/4885L3MBTL1 3241/4885GAA 4441/4885 |
| US-20040077861-A1 | Asymmetric process for the preparation of diarylethylpiperazines derivatives and novel asymmetric diarylmethylamines as intermediates | SRM, SULT2A1, PNMT | KDM4E 936/4885L3MBTL1 3241/4885GAA 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.